ARGX vs. AVTR: argenx vs. Avantor Stock Comparison
How do argenx (ARGX) and Avantor (AVTR) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.
Company Profile
argenx (ARGX) and Avantor (AVTR) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but ARGX is classified in Biotechnology while AVTR is classified in Life Sciences Tools & Services.
Avantor (AVTR) trades as ordinary local shares, while argenx (ARGX) trades as an ADR — compare with FX exposure, depositary-program fees, and dividend-withholding-tax differences in mind.
| Profile Item | ARGX | AVTR |
|---|---|---|
| Name | argenx SE American Depositary Receipt | Avantor, Inc. |
| Country/Region | Netherlands | United States |
| GICS Sector | Health Care | Health Care |
| GICS Industry Group | Pharmaceuticals, Biotechnology & Life Sciences | Pharmaceuticals, Biotechnology & Life Sciences |
| GICS Industry | Biotechnology | Life Sciences Tools & Services |
| GICS Sub-Industry | Biotechnology | Life Sciences Tools & Services |
| Market Capitalization | 58.31 billion USD | 10.48 billion USD |
| Currency | USD | USD |
| Exchange | Nasdaq | NYSE |
| Listing Date | May 18, 2017 | May 17, 2019 |
| Security Type | ADR | Common Stock |
Price Performance
Cumulative Growth
Trailing Returns
Calendar-Year Returns
Performance Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| Total Return (1Y) | 11.91% | 36.41% |
| Total Return (3Y, Annualized) | 25.68% | -5.02% |
| Total Return (5Y, Annualized) | 24.22% | -16.62% |
Risk Profile
Drawdown History
Return Distribution
Risk Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| Volatility (1Y, Annualized) | 37.87% | 43.39% |
| Beta (5Y) | 0.45 | 0.94 |
| Max Drawdown (5Y) | -38.20% | -82.42% |
| Avg. Volume (3M) | 359.84K | 8.56M |
Risk-Adjusted Performance
Risk-Return Positioning
Risk-Adjusted Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| Sharpe Ratio (1Y) | 0.20 | 0.74 |
| Sortino Ratio (1Y) | 0.31 | 1.17 |
Profitability
ROE (TTM)
Capital efficiency shows on one side only: Avantor (AVTR) earns 5.91% on shareholders’ equity, ranked against its industry; argenx (ARGX) has no ROE this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 109.18%
- Q3
- 6.23%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
- ARGX
- --
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.91%
- Max
- 109.18%
- Q3
- 6.23%
- AVTR
- 5.91%
- Median
- -26.66%
- Q1
- -64.05%
- Min
- -167.77%
Net Margin (TTM)
argenx (ARGX) at 31.73% keeps the most of each sales dollar — above its industry’s net margin range — and Avantor (AVTR) at 5.08% also retains a top-quartile share.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
31.73%
- ARGX
- 31.73%
- Max
- 18.05%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
5.08%
- Max
- 18.05%
- AVTR
- 5.08%
- Q3
- 4.78%
- Median
- 0.00%
- Q1
- -4.14%
- Min
- -17.05%
Operating Margin (TTM)
argenx (ARGX) at 36.27% operates in the top operating margin quartile, ahead of Avantor (AVTR) at 8.19%, which runs around its industry’s norm.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
36.27%
- Max
- 83.12%
- ARGX
- 36.27%
- Q3
- 14.77%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
8.19%
- Max
- 83.12%
- Q3
- 14.77%
- AVTR
- 8.19%
- Median
- 0.00%
- Q1
- -78.82%
- Min
- -207.40%
Profitability Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| ROE (TTM) | -- | 5.91% |
| ROA (TTM) | -- | 2.83% |
| Net Margin (TTM) | 31.73% | 5.08% |
| Operating Margin (TTM) | 36.27% | 8.19% |
| Gross Margin (TTM) | 59.84% | 31.59% |
Growth
Revenue Growth
argenx (ARGX) at 89.64% sits in the top revenue growth quartile, while Avantor (AVTR) at -3.41% is in the bottom quartile, showing a clear gap in revenue momentum.
EPS Growth
argenx (ARGX) at 53.13% is around its peer norm for EPS growth, while Avantor (AVTR) at -175.00% drops into the bottom quartile, signaling weaker earnings momentum.
Growth Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| Revenue Growth (YoY) | 89.64% | -3.41% |
| Revenue Growth (3Y CAGR) | 116.25% | -4.46% |
| EPS Growth (YoY) | 53.13% | -175.00% |
| EPS Growth (3Y CAGR) | -- | -- |
Financial Strength
Current Ratio (MRQ)
Short-term liquidity can only be read on one side of this pairing: Avantor (AVTR) shows current ratio of 1.89 against its industry benchmark, while argenx (ARGX) has no reading this period.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
--
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- Min
- 0.10
- ARGX
- --
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.89
- Max
- 25.13
- Q3
- 12.13
- Median
- 5.52
- Q1
- 2.47
- AVTR
- 1.89
- Min
- 0.10
Debt / Equity (MRQ)
argenx (ARGX) at 0.01 keeps leverage in the lower industry quartile, while Avantor (AVTR) at 0.63 runs a more typical debt-to-equity mix.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.01
- Max
- 1.42
- Q3
- 0.65
- Median
- 0.15
- Q1
- 0.02
- ARGX
- 0.01
- Min
- 0.00
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.63
- Max
- 1.42
- Q3
- 0.65
- AVTR
- 0.63
- Median
- 0.15
- Q1
- 0.02
- Min
- 0.00
Financial Strength Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| Current Ratio (MRQ) | -- | 1.89 |
| Debt / Equity (MRQ) | 0.01 | 0.63 |
| Net Debt / EBITDA | -2.70 | 3.40 |
Dividends
Dividend Yield (TTM)
Neither argenx (ARGX) nor Avantor (AVTR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Payout Ratio (TTM)
Neither argenx (ARGX) nor Avantor (AVTR) pays a dividend this period — they may reinvest, use buybacks, or simply not return cash through dividends.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- ARGX
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
0.00%
- AVTR
- 0.00%
- Max
- 0.00%
- Q3
- 0.00%
- Median
- 0.00%
- Q1
- 0.00%
- Min
- 0.00%
Dividend Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| Dividend Yield (TTM) | 0.00% | 0.00% |
| Dividend Payout Ratio (TTM) | 0.00% | 0.00% |
Valuation
P/E Ratio (TTM)
Both argenx (ARGX) at 32.12 and Avantor (AVTR) at 30.94 land around their industries’ usual P/E ratio levels — neither is getting a clear earnings-multiple discount or premium versus peers.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
32.12
- Max
- 85.34
- Q3
- 43.46
- ARGX
- 32.12
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
30.94
- Max
- 85.34
- Q3
- 43.46
- AVTR
- 30.94
- Median
- 26.69
- Q1
- 13.30
- Min
- 0.07
P/S Ratio (TTM)
Avantor (AVTR) at 1.58 sits in the cheaper P/S ratio quartile while argenx (ARGX) at 9.86 prices around its industry’s middle — AVTR costs less per dollar of sales, though read it alongside growth and margins.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
9.86
- Max
- 58.18
- Q3
- 25.77
- ARGX
- 9.86
- Median
- 7.30
- Q1
- 3.01
- Min
- 0.01
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.58
- Max
- 58.18
- Q3
- 25.77
- Median
- 7.30
- Q1
- 3.01
- AVTR
- 1.58
- Min
- 0.01
P/B Ratio (MRQ)
Avantor (AVTR) at 1.80 sits near its industry’s typical P/B ratio, while argenx (ARGX) at 172.23 prices above its benchmark range — ARGX looks rich relative to book.
ARGX
Pharmaceuticals, Biotechnology & Life Sciences industry group
172.23
- ARGX
- 172.23
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- Q1
- 1.69
- Min
- -5.59
AVTR
Pharmaceuticals, Biotechnology & Life Sciences industry group
1.80
- Max
- 13.53
- Q3
- 6.54
- Median
- 3.25
- AVTR
- 1.80
- Q1
- 1.69
- Min
- -5.59
Valuation Metrics
| Metric | ARGX | AVTR |
|---|---|---|
| P/E Ratio (TTM) | 32.12 | 30.94 |
| P/S Ratio (TTM) | 9.86 | 1.58 |
| P/B Ratio (MRQ) | 172.23 | 1.80 |
| Free Cash Flow Yield (TTM) | -- | 4.21% |